Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care.

JCO Precis Oncol · 2025 · PMC12462675 · PMID 40971748

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Despite these limitations, our data add to the convincing and growing body of information supporting clinically and highly significant survival benefit from administering TRK inhibitors to their respective patient population.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.